Table 1.

Clinical attributes of TNBC patients from CPTAC, TCGA, METABRIC and MET500 by TNBC subtype.

			TNBC	Basal-like 1	Basal-like 2	Mesenchy-mal	Luminal AR
Primary	Datasets	CPTAC	27	11 (40.7%)	3 (11.1%)	9 (33.3%)	4 (14.8%)
		TCGA	183	64 (35.0%)	37 (20.1%)	54 (29.5%)	28 (15.3%)
		METABRIC	348	124 (35.6%)	70 (20.1%)	71 (20.4%)	83 (23.9%)
	Age		55.7	52.7	57.9	54.8	59.9
	Stage	I	120 (26.0%)	36 (22.6%)	22 (24.1%)	30 (27.0%)	32 (33.3%)
		II	252 (52.7%)	101 (63.5%)	46 (50.5%)	59 (53.2%)	46 (47.9%)
		III	75 (16.2%)	20 (12.6%)	23 (25.3%)	20 (18.0%)	12 (12.5%)
		IV	3 (0.7%)	1 (0.6%)	0 (0.0%)	2 (1.8%)	0 (0.0%)
	Histology	IDC	476 (85.8%)	174 (87.9%)	89 (81.7%)	116 (87.2%)	97 (82.9%)
		ILC	26 (4.9%)	4 (2.1%)	3 (2.8%)	4 (3.2%)	15 (13.5%) p = 8.88e−6
		Mixed	1 (0.1%)	1 (1.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Mucinous	1 (0.1%)	1 (1.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Medullary	29 (5.6%)	18 (9.6%) p = 0.0041	7 (6.5%)	1 (1.8%)	3 (2.7%)
		Metaplastic	14 (2.6%)	0 (0.0%)	7 (13.5%) p = 0.011	6 (5.6%)	1 (0.8%)
		Phyllodes tumor	4 (0.8%)	0 (0.0%)	0 (0.0%)	4 (3.2%) p = 0.0026	0 (0.0%)
		Neuroendocrine	1 (0.1%)	0 (0.0%)	0 (0.0%)	1 (1.8%)	0 (0.0%)
		Secretory	1 (0.1%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
		Papillary	1 (0.1%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	0 (0.0%)
		Other	2 (0.3%)	0 (0.0%)	1 (0.9%)	1 (0.8%)	0 (0.0%)
		NA	4 (0.8%)	1 (1.6%)	1 (0.9%)	0 (0.0%)	2 (1.7%)
Metastatic	Datasets	MET500	40	11 (27.5%)	10 (25.0%)	8 (20.0%)	10 (25.0%)

Parentheses indicate the percentage of tumors within each column of primary or metastatic disease. Chi-squared testing was performed with statistically significant comparisons indicated in bold text.

Abbreviations: IDC invasive ductal carcinoma, ILC invasive lobular carcinoma.